Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pimpinella brachycarpa extract (PBE) is a plant-derived herbal medicine currently in the research phase for the treatment of periodontitis. Derived from a plant traditionally used in Asian medicine for its anti-inflammatory and antimicrobial properties, PBE has demonstrated significant efficacy in preclinical models of ligature-induced periodontitis. Its therapeutic effect is mediated through the suppression of pro-inflammatory cytokines, specifically tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), and the inhibition of osteoclastogenesis, which prevents alveolar bone loss. Chemical analysis identifies chlorogenic acid as a primary active constituent responsible for these bone-protective and anti-inflammatory effects. Studies published in 2025 indicate that oral administration of the extract can significantly reduce inflammatory responses and bone resorption, showing potential as a therapeutic agent for periodontal diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pimpinella brachycarpa extract.